✦ LIBER ✦

251 Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma

✍ Scribed by CORREN, J; FROEHLICH, J; SCHOENHOFF, M; SPECTOR, S; RACHELEFSKY, G; SCHANKER, H; PATNAIK, M; SIEGEL, S

Book ID: 119495575
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 124 KB
Volume: 97
Category: Article
ISSN: 1097-6825
DOI: 10.1016/s0091-6749(96)80469-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treating Moderate-to-Severe Allergic Ast

Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab)

✍ Prof. Gennaro D’Amato, Enrica Bucchioni… 📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 92 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB